ES2185595T3 - Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas. - Google Patents

Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.

Info

Publication number
ES2185595T3
ES2185595T3 ES00932570T ES00932570T ES2185595T3 ES 2185595 T3 ES2185595 T3 ES 2185595T3 ES 00932570 T ES00932570 T ES 00932570T ES 00932570 T ES00932570 T ES 00932570T ES 2185595 T3 ES2185595 T3 ES 2185595T3
Authority
ES
Spain
Prior art keywords
peptides
viric
infections
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00932570T
Other languages
English (en)
Other versions
ES2185595T5 (es
Inventor
Dominique P Bridon
Robert S Dufresne
Nissab Boudjellab
Martin Robitaille
Peter G Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2185595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of ES2185595T3 publication Critical patent/ES2185595T3/es
Application granted granted Critical
Publication of ES2185595T5 publication Critical patent/ES2185595T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Péptido antiviral modificado que comprende: ¿ un péptido que muestra actividad antiviral, y ¿ un grupo maleimido que es reactivo con un grupo tiol en componentes sanguíneos para formar enlaces covalentes estables.
ES00932570T 1999-05-17 2000-05-17 Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas. Expired - Lifetime ES2185595T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US134406P 1999-05-17
US15340699P 1999-09-10 1999-09-10
US153406P 1999-09-10

Publications (2)

Publication Number Publication Date
ES2185595T3 true ES2185595T3 (es) 2003-05-01
ES2185595T5 ES2185595T5 (es) 2009-12-17

Family

ID=26832297

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02014617T Expired - Lifetime ES2334106T3 (es) 1999-05-17 2000-05-17 Inhibidores peptidos de fusion de larga vida contra infecciones virales.
ES00932570T Expired - Lifetime ES2185595T5 (es) 1999-05-17 2000-05-17 Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02014617T Expired - Lifetime ES2334106T3 (es) 1999-05-17 2000-05-17 Inhibidores peptidos de fusion de larga vida contra infecciones virales.

Country Status (14)

Country Link
US (4) US7582301B1 (es)
EP (3) EP2110381A1 (es)
JP (3) JP4216480B2 (es)
CN (1) CN1351611A (es)
AT (2) ATE226593T1 (es)
AU (1) AU761591B2 (es)
BR (1) BR0010757A (es)
CA (1) CA2372338A1 (es)
DE (2) DE60000665T3 (es)
DK (1) DK1264840T3 (es)
ES (2) ES2334106T3 (es)
HK (1) HK1053128A1 (es)
PT (1) PT1264840E (es)
WO (1) WO2000069902A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ES2334106T3 (es) 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
ATE345353T1 (de) 2001-05-31 2006-12-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
JP4267444B2 (ja) 2001-06-15 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー Ｇｐ４１フラグメントのアセチル化
US7575750B2 (en) 2002-09-24 2009-08-18 Frontiers Biotechnologies Col, Ltd. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP2418281B1 (en) 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DK1745078T3 (da) * 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101415723B (zh) 2006-02-02 2014-06-25 特里梅里斯公司 具有改良生物学特性的hiv融合抑制肽
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
WO2008019817A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
TW200902544A (en) * 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
AU2008254767A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CN101835801B (zh) 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
KR101425404B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
JP5757639B2 (ja) 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2834264A1 (en) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
WO2014165452A1 (en) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions and methods for inhibiting viral activity
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0578728B1 (en) 1991-04-05 1998-07-01 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
CA2301799C (en) * 1997-11-07 2007-08-07 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
ATE406577T1 (de) * 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
AU748496B2 (en) 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
ES2334106T3 (es) * 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
ATE345353T1 (de) 2001-05-31 2006-12-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
DK1745078T3 (da) * 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
WO2005108418A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Also Published As

Publication number Publication date
BR0010757A (pt) 2002-02-19
EP1179012A1 (en) 2002-02-13
DE60043021D1 (de) 2009-11-05
US7608271B2 (en) 2009-10-27
US20080176794A1 (en) 2008-07-24
JP2008101021A (ja) 2008-05-01
WO2000069902A1 (en) 2000-11-23
ATE226593T1 (de) 2002-11-15
JP2002544287A (ja) 2002-12-24
EP1264840A1 (en) 2002-12-11
EP1264840B1 (en) 2009-09-23
EP1179012B2 (en) 2009-07-15
US20050070475A1 (en) 2005-03-31
DE60000665T3 (de) 2009-10-29
EP1179012B1 (en) 2002-10-23
AU5027100A (en) 2000-12-05
CA2372338A1 (en) 2000-11-23
DE60000665D1 (de) 2002-11-28
JP2009167208A (ja) 2009-07-30
US20080199483A1 (en) 2008-08-21
CN1351611A (zh) 2002-05-29
ATE443714T1 (de) 2009-10-15
JP4216480B2 (ja) 2009-01-28
HK1053128A1 (en) 2003-10-10
ES2185595T5 (es) 2009-12-17
PT1264840E (pt) 2010-01-04
US7582301B1 (en) 2009-09-01
DE60000665T2 (de) 2003-06-26
ES2334106T3 (es) 2010-03-05
EP1179012B9 (en) 2003-09-10
AU761591B2 (en) 2003-06-05
DK1264840T3 (da) 2009-11-16
EP2110381A1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
LU92175I2 (fr) Lixisénatide
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ATE331730T1 (de) Neue depsipeptid-verbindung
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum